The OIG has released its annual “Compendium of Unimplemented Office of Inspector General Recommendations,” outlining previous OIG recommendations that the agency believes could achieve substantial savings and increase the effectiveness of HHS programs. Priority recommendations listed in the report address the following issue areas:

  • Oversight of Medicare Part D -- Ensure accurate Medicare Part D sponsors bids and prospective payments; and implement safeguards to prevent and detect fraud and abuse in Medicare prescription drug plans.
  • Medicare Integrity -- Ensure DME suppliers’ compliance with Medicare standards, modify Medicare hospital bad debt policy; reduce the rental period for Medicare home oxygen equipment; modify payments to managed care organizations; place a ceiling on administration costs included in managed care organizations’ rate proposals; and improve CMS performance evaluation process for program safeguard contractors.
  • Medicaid and SCHIP Integrity -- Extend additional rebate payment provision to generic drugs; limit enhanced payments to cost and require that Medicaid payments returned by public providers be used to offset the federal share, resolve excessive Medicaid disproportionate share hospital payments; ensure Medicaid reimbursement for brand-name and generic drugs accurately reflects pharmacy acquisition costs, and link Medicaid drug rebate and drug reimbursement calculations.
  • Quality of Care -- Ensure the appropriate processing of denial of Medicare payment remedies for noncompliant nursing homes; and improve Medicare hospice oversight.
  • Oversight of Food, Drugs, and Medical Devices -- Update and maintain an accurate new drug code directory; improve FDA postmarketing oversight of drugs.
  • Grants Management -- Increase oversight of NIH’s grantee institutions to ensure their compliance with federal financial conflict-of-interest regulations.
  • Ethics Program Oversight and Enforcement -- Strengthen FDA oversight of clinical investigators.